Background
Emotional symptoms are recognized as a key feature in individuals with major depressive disorder. Previously, emotional blunting has been described both as a side-effect of antidepressant treatment and as a symptom of depression. Little is known on the change of emotional blunting during antidepressant treatment.
Methods
The PREDDICT trial is a randomized, placebo-controlled, 6-week trial on the augmentation of vortioxetine with the anti-inflammatory agent celecoxib or placebo. Presently we report on exploratory secondary outcomes of changes in emotional blunting in depression assessed with the Oxford Depression Questionnaire (ODQ) total score and sub-scores from baseline to 8-week, 3-month, and 6-month follow-up assessments.
Results
In the whole group, there was a significant improvement in ODQ total score and all sub-scores after 8 weeks. After stratification of participants into the treatment groups, the ODQ total score as well as sub-scores related to emotional blunting as a symptom of depression (reduction in positive emotions, not caring) improved between baseline and all follow-up time points in both treatment groups. Changes in sub-scores which are considered as a side-effect of antidepressants (general reduction in emotions, emotional detachment) were inconclusive in both treatment groups. Overall, the placebo-augmented group showed slightly better results in changes of emotional blunting scores than the celecoxib group, as did those with elevated inflammation at screening, regardless of treatment group.
Conclusions
This analysis suggests favourable effects of vortioxetine on emotional blunting both in short and long-term course. The beneficial impact of vortioxetine on emotional blunting was weaker in celecoxib-augmented patients compared to placebo, possibly due to pharmacokinetic interactions.